1,041 material Form 8-K filings that 824 companies we cover made with the SEC in November 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
EPAM Systems reported third-quarter 2025 revenue of $1.394 billion, up 19.4% from a year earlier, while GAAP diluted EPS fell 19.4% to $1.91 and non-GAAP diluted EPS fell 1.3% to $3.08. The company raised its full-year 2025 revenue outlook to $5.430 billion to $5.445 billion and its full-year EPS outlook, and expects fourth-quarter revenue of $1.380 billion to $1.395 billion. Shareholders also received an update on capital returns, including $82.1 million of buybacks in the quarter and a new $1.0 billion repurchase program approved October 16, 2025.
Q3 2025 revenue of $1.394 billion, up 19.4% year over year; organic constant currency growth was 7.1%
Q3 GAAP diluted EPS of $1.91, down $0.46 or 19.4%; non-GAAP diluted EPS of $3.08, down $0.04 or 1.3%
Full-year 2025 revenue outlook raised to $5.430 billion to $5.445 billion; GAAP diluted EPS outlook $6.75 to $6.83, non-GAAP $11.36 to $11.44
Repurchased $82.1 million of stock in Q3; board approved a new repurchase program of up to $1.0 billion on October 16, 2025
Talos Energy reported a third-quarter 2025 net loss of $95.9 million, or $0.55 per diluted share, which includes a $60.2 million non-cash impairment, on total revenues of $450.1 million. The company also raised its full-year 2025 average daily production guidance to 94.0 to 97.0 MBoe/d and lowered its cash operating expense and capital expenditure ranges.
Q3 2025 net loss of $95.9 million ($0.55 per diluted share); adjusted net loss of $33.0 million ($0.19 per share)
Full-year 2025 production guidance raised to 94.0-97.0 MBoe/d from 91.0-95.0 MBoe/d
Full-year 2025 capital expenditure guidance lowered to $480-520 million from $490-530 million
Repurchased about 5.0 million shares for $48.1 million in Q3; $332.7 million cash at September 30, 2025
LifeStance reported third-quarter 2025 results on November 6, 2025, with revenue of $363.8 million, up 16% from a year earlier, and net income of $1.1 million compared with a net loss of $6.0 million in the prior-year quarter. The company raised its full-year 2025 Adjusted EBITDA guidance to $146 million to $152 million and raised the midpoint of its Center Margin expectations, while reiterating its full-year revenue outlook of $1.41 billion to $1.43 billion.
Q3 2025 revenue of $363.8 million, up 16%; clinician base rose 11% to 7,996.
Net income of $1.1 million versus a $6.0 million net loss a year earlier; Adjusted EBITDA of $40.2 million, up 31%.
Full-year 2025 Adjusted EBITDA guidance raised to $146 million to $152 million; revenue guidance reiterated at $1.41 billion to $1.43 billion.
Fourth-quarter 2025 outlook: total revenue of $368 million to $388 million and Adjusted EBITDA of $37 million to $43 million.
Kinetik reported third-quarter 2025 net income including noncontrolling interest of $15.5 million, down from $83.7 million a year earlier, while total operating revenues rose to $464.0 million from $396.4 million. The company now expects full-year 2025 Adjusted EBITDA of $965 million to $1.005 billion, citing slower Kings Landing ramp-up, producer delays, lower commodity prices, and the October EPIC Crude sale.
Q3 2025 diluted EPS attributable to Class A holders was $0.03, versus $0.35 in Q3 2024
Q3 Adjusted EBITDA was $242.6 million, versus $265.7 million a year earlier
2025 Adjusted EBITDA guidance revised to $965 million to $1.005 billion; 2025 capital guidance tightened to $485 million to $515 million
Closed sale of 27.5% EPIC Crude interest in October 2025 with over $500 million in net upfront cash
Dorian LPG reported results for the quarter ended September 30, 2025, with revenues of $124.1 million, up 50.5% from a year earlier, and net income of $55.4 million, or $1.30 per diluted share, compared with $9.4 million, or $0.22, a year earlier. The board also declared an irregular cash dividend of $0.65 per share, about $27.8 million in total, which the company says is not a recurring payment.
Revenues of $124.1 million for the quarter, up $41.7 million, or 50.5%, from $82.4 million
Net income of $55.4 million, or $1.30 per diluted share, versus $9.4 million, or $0.22, in the prior-year quarter
Irregular dividend of $0.65 per share, about $27.8 million, payable on or about December 2, 2025 to holders of record on November 17, 2025
Time charter equivalent rate per available day rose to $53,725 from $37,010, a 45.2% increase
PTC entered into an agreement on November 5, 2025 to sell its ThingWorx and Kepware businesses to Parrot US Buyer, L.P., an entity controlled by funds affiliated with TPG Global, for $600 million in cash plus assumed liabilities. The filing says the deal is part of portfolio simplification, and the closing depends on regulatory approvals and is not subject to a financing condition or PTC shareholder approval.
Cash purchase price of $600 million, plus assumption of certain Business liabilities and contingent consideration of up to $125 million after a later sale by the buyer.
Price is subject to adjustments for working capital, indebtedness, and a $35 million reduction if the Business does not meet certain financial metrics in the month before closing.
Closing expected on the later of February 1, 2026 and the second business day after closing conditions are met, subject to HSR Act and foreign regulatory approvals.
Either party may terminate if the deal is not completed by August 5, 2026, with that date extended to November 5, 2026 if only certain regulatory approvals remain outstanding.
STERIS reported fiscal 2026 second-quarter results for the quarter ended September 30, 2025, with revenue from continuing operations up 10% to $1.5 billion and diluted EPS from continuing operations rising to $1.94 from $1.51 a year earlier. The company raised its fiscal 2026 adjusted EPS outlook to $10.15 to $10.30 and its free cash flow expectation to about $850 million, which points to higher expected per-share earnings and cash generation for shareholders.
Q2 revenue from continuing operations rose to $1,460.3 million from $1,328.9 million; constant currency organic growth was 9%.
Diluted EPS from continuing operations was $1.94 vs. $1.51; adjusted EPS was $2.47 vs. $2.14.
Fiscal 2026 adjusted EPS outlook raised to $10.15 to $10.30 from $9.90 to $10.15; free cash flow expected at about $850 million vs. $820 million prior.
Tariffs are estimated to reduce pre-tax profit by about $45 million, unchanged from prior outlook.
Interparfums reported third-quarter 2025 net income attributable to the company of $66 million, or $2.05 per diluted share, up 6% from a year earlier, on net sales of $430 million (up 1%). For the first nine months, net income was flat at $140 million. Management updated 2025 guidance to $1.47 billion in sales (up 1%) and diluted EPS of $5.12 (flat versus 2024), citing slower-than-anticipated growth through September and softer demand in several international markets.
Q3 2025 net sales $430 million, up 1%; diluted EPS $2.05 vs. $1.93 a year earlier
Nine-month net sales $1.10 billion, up 1%; diluted EPS $4.36 vs. $4.34
Updated full-year 2025 guidance: $1.47 billion in sales and $5.12 diluted EPS; 2026 initial guidance due November 18, 2025
Quarterly dividend of $0.80 per share payable December 31, 2025, to holders of record December 15, 2025
Ingevity reported third-quarter 2025 results and revised its full-year 2025 guidance to total net sales of $1.25 billion to $1.35 billion and total adjusted EBITDA of $390 million to $405 million. The company said the revision reflects challenges in its Advanced Polymer Technologies segment, and it reported $43.5 million in net income, including discontinued operations, compared with a net loss of $107.2 million a year earlier.
Net sales from continuing operations were $333.1 million, flat compared with the prior year quarter.
Diluted EPS was $1.18 in the quarter, versus a diluted loss per share of $2.94 a year earlier; continuing operations diluted EPS was $1.10.
Full-year 2025 guidance: total net sales of $1.25 billion to $1.35 billion and total adjusted EBITDA of $390 million to $405 million.
The sale of most of the Industrial Specialties product line and the North Charleston crude tall oil refinery for $110 million is expected to close by early 2026.
Rayonier reported third quarter 2025 net income attributable to Rayonier of $43.2 million ($0.28 per share) on revenues of $177.5 million, up from $28.8 million ($0.19 per share) on $124.1 million a year earlier. The company now expects full-year Adjusted EBITDA at or above the higher end of its prior guidance range, though it expects Southern Timber to fall modestly below its range and Pacific Northwest Timber toward the lower end.
Q3 pro forma net income was $50.2 million ($0.32 per share) versus $11.1 million ($0.07) a year earlier; Adjusted EBITDA was $114.3 million versus $57.2 million.
Real Estate Adjusted EBITDA was $73.8 million, and the company expects full-year Real Estate Adjusted EBITDA to exceed the high end of its prior range.
Q4 outlook: net income attributable to Rayonier of $13 to $17 million, EPS of $0.08 to $0.11, and Adjusted EBITDA of $50 to $60 million.
Quarter-end cash balance was $919.6 million; the company repurchased 1,226,384 shares for $30.1 million and expects the PotlatchDeltic merger to close in late first quarter or early second quarter 2026.
Phibro Animal Health reported fiscal first-quarter results ended September 30, 2025, with net sales up 40% to $363.9 million and diluted earnings per share of $0.65, compared with $0.17 a year earlier. The company raised its fiscal 2026 adjusted EBITDA guidance to $230 million to $240 million and kept its net sales guidance at $1.43 billion to $1.48 billion.
Quarterly net sales of $363.9 million, up $103.5 million, or 40%, with Animal Health sales up 55% to $283.5 million
Diluted EPS of $0.65 versus $0.17, and adjusted diluted EPS of $0.73 versus $0.35
Fiscal 2026 adjusted EBITDA guidance raised to $230 million to $240 million; net sales guidance of $1.43 billion to $1.48 billion maintained
At the November 4, 2025 annual meeting, stockholders elected three Class III directors, approved executive pay on an advisory basis, and ratified PricewaterhouseCoopers LLP as auditor
Ameren reported third quarter 2025 GAAP net income of $640 million, or $2.35 per diluted share, up from $456 million, or $1.70, a year earlier. Adjusted diluted EPS was $2.17, compared with $1.87. The company raised its 2025 GAAP EPS guidance to $5.08 to $5.28 and set 2026 diluted EPS guidance at $5.25 to $5.45, though the quarter included a $48 million tax benefit that the company excluded from adjusted results.
Q3 2025 GAAP diluted EPS was $2.35 vs. $1.70 in Q3 2024; adjusted diluted EPS was $2.17 vs. $1.87.
Q3 2025 included a $48 million ($0.18 per share) tax benefit from a FERC order on net operating loss carryforwards, excluded from adjusted earnings.
2025 GAAP EPS guidance raised to $5.08 to $5.28 and adjusted EPS guidance to $4.90 to $5.10, both up from the original $4.85 to $5.05 range.
2026 diluted EPS guidance set at $5.25 to $5.45; analyst call scheduled for 9 a.m. Central Time on November 6, 2025.
Host Hotels & Resorts reported third quarter 2025 revenues of $1,331 million, up 0.9% from a year earlier, and GAAP net income of $163 million, up from $84 million, which the company said benefited from a gain on the sale of the Washington Marriott at Metro Center. Adjusted EBITDAre fell 3.3% to $319 million, and the company raised its full-year 2025 guidance, including net income of $780 million and diluted earnings per share of $1.11.
Q3 2025 revenues were $1,331 million, up 0.9%; diluted earnings per share were $0.23 versus $0.12 in Q3 2024.
Comparable hotel RevPAR rose 0.2% to $208.07; comparable hotel Total RevPAR rose 0.8% to $335.42.
Full-year 2025 guidance: comparable hotel RevPAR growth of about 3.0%, net income of $780 million, and Adjusted EBITDAre of $1,730 million, up from prior midpoints of $616 million and $1,705 million respectively.
Agreement with Marriott to spend $300 million to $350 million through 2029 on a second transformational capital program at four properties.
Watts Water Technologies reported third quarter 2025 net sales of $611.7 million, up 13% from a year earlier, with diluted EPS of $2.45, up 19%. The company raised its full-year 2025 sales and margin outlook and said it acquired Haws Corporation on November 4, 2025, which shareholders may weigh against higher-than-prior-year sales and profit.
Net sales of $611.7 million, up 13% on a reported basis and 9% organically; Europe organic sales fell 2%
Diluted EPS of $2.45 versus $2.06; adjusted diluted EPS of $2.50 versus $2.03
Full-year 2025 reported sales growth now expected at 7% to 8%; adjusted operating margin expected at 19.1% to 19.2%
Enact Holdings reported third-quarter 2025 net income of $163 million, or $1.10 per diluted share, down from $181 million, or $1.15 per share, a year earlier, and slightly below the second quarter's $168 million. The company raised its expected total 2025 capital return to approximately $500 million and declared a $0.21 quarterly dividend, while the loss ratio rose to 15% from 5% a year ago.
Net income was $163 million, or $1.10 per diluted share, versus $181 million, or $1.15, in Q3 2024
Adjusted operating income was $166 million, or $1.12 per diluted share, versus $182 million, or $1.16, in Q3 2024
Loss ratio was 15%, compared with 5% in Q3 2024 and 10% in Q2 2025
Expected total 2025 capital return raised to approximately $500 million; $0.21 dividend payable December 11, 2025
Crane NXT reported third quarter 2025 net sales of $445.1 million, up 10.3% from a year earlier, with GAAP EPS of $0.87 versus $0.81 and Adjusted EPS of $1.28 versus $1.16. The company raised its full-year sales growth guidance to 9% to 11% but narrowed its Adjusted EPS guidance to $4.00 to $4.10, down from $4.00 to $4.30 at the top end, citing macroeconomic uncertainty affecting demand in its CPI segment.
Q3 net sales of $445.1 million rose 10.3%, including a $28.3 million benefit from the De La Rue Authentication Solutions acquisition; GAAP EPS was $0.87 versus $0.81.
Adjusted EPS was $1.28 versus $1.16 in the prior-year quarter.
Full-year 2025 sales growth guidance raised to +9% to +11% from +6% to +8%.
Adjusted EPS guidance narrowed to $4.00 to $4.10 from $4.00 to $4.30; quarterly dividend of $0.17 per share is payable December 10, 2025.
Marriott Vacations Worldwide reported a third-quarter 2025 net loss attributable to common stockholders of $2 million, or $0.07 per diluted share, compared with net income of $84 million a year earlier. It also cut its full-year 2025 Adjusted EBITDA and Adjusted free cash flow guidance, while raising the low end of its Adjusted EPS range, which matters to shareholders because the outlook for earnings and cash generation was lowered.
Q3 2025 net loss attributable to common stockholders was $2 million, or $0.07 per diluted share, versus net income of $84 million, or $2.12 per diluted share, in Q3 2024.
Q3 2025 Adjusted EBITDA was $170 million, down 15% from $200 million; consolidated contract sales were $439 million, down 4%.
Full-year 2025 Adjusted EBITDA guidance is $740 million to $755 million, down from $750 million to $780 million; Adjusted free cash flow guidance is $235 million to $270 million, down from $270 million to $330 million.
Full-year 2025 Adjusted EPS guidance is $6.70 to $7.10, up from $6.40 to $7.10; the company will hold a conference call on November 6, 2025 at 8:30 a.m. ET.
Q2 Holdings announced executive changes effective November 6, 2025. Himagiri Mukkamala, Chief Development Officer, becomes Chief Operating Officer, Kirk L. Coleman moves from President to Chief Business Officer, and Matthew P. Flake takes on the President title alongside his roles as Chairman and CEO. Chief Revenue Officer Michael A. Volanoski is leaving the company, staying through December 12, 2025 to help with the transition.
Mukkamala's annual base salary rises to $450,000 with a target bonus of 75% of base salary, effective November 6, 2025
Coleman resigns as President effective November 6, 2025 and becomes Chief Business Officer
Volanoski will depart and continue as Chief Revenue Officer through December 12, 2025; his exit is not tied to any dispute with the company
Filing states no compensation changes for Coleman or Flake from the leadership changes
Genworth reported third-quarter 2025 net income available to common stockholders of $116 million, or $0.28 per diluted share, up from $51 million in the prior quarter and $85 million a year earlier. Adjusted operating income fell to $17 million, or $0.04 per diluted share, from $68 million in the prior quarter and $48 million a year earlier. The company also announced a new $350 million share repurchase authorization, and the GAAP result was helped by $78 million of net investment gains and a $34 million tax benefit.
Net income available to common stockholders was $116 million ($0.28 diluted), versus $51 million in Q2 2025 and $85 million in Q3 2024.
Adjusted operating income was $17 million ($0.04 diluted), versus $68 million in Q2 2025 and $48 million in Q3 2024.
Net income included a $34 million tax benefit and $78 million of net investment gains; Long-Term Care Insurance adjusted operating loss was $100 million.
Board authorized a new $350 million share repurchase program; $76 million was executed in the quarter.
Q2 Holdings reported third-quarter 2025 revenue of $201.7 million, up 15 percent year over year, and GAAP net income of $15.0 million, compared with a net loss of $11.8 million a year earlier. The company raised its full-year 2025 revenue and adjusted EBITDA guidance and authorized up to $150 million in share repurchases, which it expects to fund from existing cash. Shareholders also face an executive change, as the chief revenue officer will leave on December 12, 2025.
Q3 2025 revenue was $201.7 million, up 15 percent year over year; GAAP net income was $15.0 million, or $0.23 diluted EPS, versus a net loss of $11.8 million a year earlier
Adjusted EBITDA was $48.8 million, up from $32.6 million in the prior-year quarter
Full-year 2025 guidance raised to revenue of $789.0 million to $793.0 million and adjusted EBITDA of $182.5 million to $185.5 million
Board authorized repurchases of up to $150 million of common stock with no expiration date; Chief Revenue Officer Mike Volanoski will depart effective December 12, 2025
Mohawk Industries said CFO James F. Brunk will retire effective April 1, 2026, and will continue in a senior advisory role. Nicholas P. Manthey, currently Vice President of Corporate Finance and Investor Relations, will succeed him as chief financial officer. The filing does not report any financial results, and the change is a planned leadership transition.
Brunk retires as CFO effective April 1, 2026, and will serve in a senior advisory role afterward
Manthey, age 44, joined the company in 2020 as CFO of Flooring North America and has been Vice President of Corporate Finance and Investor Relations since 2024
Brunk will receive a $1,200,000 annual base salary as senior advisor and a $1,000,000 grant of common stock that vests in equal amounts over two years
Albemarle reported third-quarter 2025 net sales of $1.3 billion, down 3.5% from a year earlier, mainly on lower Energy Storage pricing. The company posted a net loss of $161 million, or $1.72 per diluted share, which includes a non-cash goodwill impairment charge tied to Ketjen, but adjusted EBITDA rose 7% to $226 million and management said full-year 2025 results are now expected toward the higher end of its $9/kg lithium price scenario ranges, which matters to shareholders because it signals a stronger expected year despite the charge.
Net sales were $1.3 billion, down 3.5% from $1.35 billion in the third quarter of 2024; Energy Storage pricing fell 16% while volumes rose 8%.
Net loss attributable to Albemarle was $161 million, or $1.72 per diluted share, including a $181 million goodwill impairment charge associated with Ketjen.
Adjusted EBITDA was $226 million, up 7%; adjusted loss was $0.19 per diluted share versus $1.55 a year earlier.
Full-year 2025 outlook was enhanced toward the higher end of the $9/kg scenario ranges, capital expenditures are now expected at about $600 million, and positive free cash flow of $300 million to $400 million is expected.
Global Net Lease reported third-quarter 2025 revenue of $121.0 million, down from $138.7 million a year earlier, mainly due to asset dispositions including the multi-tenant retail portfolio sale. It raised its full-year 2025 AFFO per share guidance to $0.95 to $0.97 from $0.92 to $0.96, and Fitch upgraded its corporate credit rating to investment-grade BBB-. For shareholders, lower revenue and AFFO per share were partly offset by a narrower net loss, the higher guidance range and a $2.0 billion reduction in net debt since third quarter 2024.
Q3 2025 revenue was $121.0 million versus $138.7 million in Q3 2024; AFFO was $53.2 million, or $0.24 per share, versus $73.9 million, or $0.32 per share
Net loss attributable to common stockholders narrowed to $71.1 million from $76.6 million a year earlier
Full-year 2025 AFFO per share guidance raised to $0.95 to $0.97 from $0.92 to $0.96; Net Debt to Adjusted EBITDA guidance unchanged at 6.5x to 7.1x
Fitch upgraded the corporate credit rating to investment-grade BBB- from BB+; company completed a $1.8 billion refinancing of its Revolving Credit Facility and repurchased 12.1 million shares for $91.7 million year-to-date through October 3
Effective October 31, 2025, Apogee Enterprises replaced CEO Ty Silberhorn, who also left the Board, with Independent Chair Donald Nolan, who becomes CEO and Executive Chair. The Board has begun evaluating internal and external CEO succession candidates, and the company reaffirmed its fiscal 2026 outlook for net sales of $1.39 billion to $1.42 billion and adjusted diluted EPS of $3.60 to $3.90.
Donald A. Nolan becomes CEO and Executive Chair effective October 31, 2025; Patricia K. Wagner named Lead Independent Director
Silberhorn's separation agreement provides $932,000 in cash in 24 monthly installments, accelerated vesting of 78,376 restricted shares, a $466,000 incentive payment, and a $742,500 cash payment plus 16,867 performance award shares
Nolan's offer letter runs through October 31, 2026, with a $925,000 base salary, a $100,000 travel payment, and a restricted stock award valued at $1.75 million
Fiscal 2026 outlook reaffirmed: net sales of $1.39 billion to $1.42 billion and adjusted diluted EPS of $3.60 to $3.90
Deluxe reported third quarter 2025 revenue of $540.2 million, up 2.2% from a year earlier, and net income of $33.7 million, up from $8.9 million. The company raised its full-year 2025 adjusted diluted EPS guidance to $3.45 to $3.60 and kept its revenue, adjusted EBITDA, and free cash flow outlook within narrowed ranges.
Q3 2025 revenue was $540.2 million, up 2.2% from $528.4 million; comparable adjusted revenue rose 2.5%.
Q3 comparable adjusted diluted EPS was $1.09, up 29.8% from $0.84; GAAP diluted EPS was $0.74 versus $0.20.
Full-year 2025 adjusted diluted EPS guidance was raised to $3.45 to $3.60; revenue guidance of $2.11 to $2.13 billion was affirmed.
Free cash flow for the first nine months was $95.9 million, up $31.6 million; the board approved a $0.30 quarterly dividend payable December 1, 2025.
Tutor Perini reported third-quarter 2025 revenue of $1.42 billion, up 31% from $1.08 billion a year earlier, and swung to diluted earnings of $0.07 per share from a loss of $1.92 per share. The company raised its 2025 Adjusted EPS guidance to $4.00 to $4.20 from $3.65 to $3.95, its third consecutive increase, and reported a record backlog of $21.6 billion.
Q3 2025 revenue of $1.42 billion, up 31% from $1.08 billion in Q3 2024
Diluted EPS of $0.07 versus a loss of $1.92 a year earlier; Adjusted EPS of $1.15 versus an adjusted loss of $1.61
2025 Adjusted EPS guidance raised to $4.00 to $4.20 from $3.65 to $3.95; GAAP EPS guidance no longer provided
Record backlog of $21.6 billion at September 30, 2025, up 54%; Q3 operating cash flow of $289.1 million
Innoviva reported third-quarter 2025 total revenue of $107.8 million, up 20% from a year earlier, and net income of $89.9 million, or $1.30 basic per share, compared with $1.2 million in the prior-year quarter. Income from operations fell 20% to $34.6 million, which the company attributed mainly to a non-recurring research and development expense, while net favorable changes in investment fair values drove the higher net income. The company also announced a new share repurchase program of up to $125 million.
Total revenue was $107.8 million, up 20% from $89.5 million in Q3 2024.
Net income was $89.9 million, or $1.30 basic per share, versus $1.2 million, or $0.02 per share, a year earlier.
Income from operations was $34.6 million, down 20% from $43.2 million, mainly due to a non-recurring R&D expense.
Board authorized a new share repurchase program of up to $125.0 million, with no termination date.
Texas Pacific Land reported third-quarter 2025 net income of $121.2 million, or $5.27 per diluted share, up from $116.1 million in the second quarter, on total revenues of $203.1 million. The board also approved a three-for-one stock split, expected in December 2025, which will change per-share figures once effective.
Q3 2025 total revenues were $203.1 million versus $187.5 million in Q2 2025; diluted EPS was $5.27 versus $5.05.
Water Services and Operations segment revenues were $80.8 million, a company record.
Three-for-one stock split approved November 3, 2025; expected to be completed in December 2025, subject to the Board setting the effective date.
Royalty acquisition of about 17,306 net acres closed November 3, 2025 for $474.1 million in cash; quarterly dividend of $1.60 per share payable December 15, 2025.
Pebblebrook Hotel Trust reported third-quarter 2025 results, showing a $32.4 million net loss compared with $45.1 million of net income a year earlier. Adjusted EBITDAre fell 11.6% to $99.2 million, and the company trimmed the midpoint of its 2025 Adjusted EBITDAre outlook by $3.0 million, while the Adjusted FFO per diluted share midpoint was unchanged.
Q3 net loss of $32.4 million, versus net income of $45.1 million in Q3 2024; the quarter included a $46.5 million impairment charge
Q3 Adjusted EBITDAre of $99.2 million, down from $112.2 million; Adjusted FFO per diluted share of $0.51, down from $0.59
Total revenues of $398.7 million, down from $404.5 million a year earlier
2025 outlook: Adjusted EBITDAre of $332.5 million to $341.5 million, midpoint reduced by $3.0 million; Adjusted FFO per diluted share of $1.50 to $1.57, midpoint unchanged
Corpay reported third-quarter 2025 revenue of $1,172.5 million, up 14%, with GAAP diluted EPS of $3.91 versus $3.90 a year earlier, and raised its full-year 2025 outlook. The company also completed the Alpha Group acquisition on October 31, 2025, for about £1.8 billion in cash, funded by borrowings under an amended credit facility that adds a $900 million Term Loan B.
Q3 2025 revenue was $1,172.5 million, up from $1,029.2 million; net income attributable to Corpay was $277.9 million, versus $276.4 million.
Adjusted net income per diluted share rose 14% to $5.70 from $5.00.
Full-year 2025 revenue guidance was raised to $4,505 million to $4,525 million, and GAAP diluted EPS guidance to $15.88 to $16.08.
The Alpha acquisition closed October 31, 2025; on November 5, 2025, Revolver B commitments rose $1 billion to $1.5 billion and a $900 million Term Loan B maturing November 5, 2032 was added.
Third-quarter oil and gas sales rose to $1.32 billion from $1.22 billion a year earlier, but net income attributable to Class A shareholders fell to $59.2 million, or $0.08 per diluted share, from $386.4 million, or $0.53. The filing also shows a $264.3 million loss on extinguishment of debt, compared with $5.1 million a year earlier. The company raised its midpoint 2025 production guidance and said no other guidance ranges changed.
Oil and gas sales were $1.32 billion for the quarter ended September 30, 2025, versus $1.22 billion a year earlier.
Net income attributable to Class A Common Stock was $59.2 million ($0.08 diluted), versus $386.4 million ($0.53) in the third quarter of 2024.
Loss on extinguishment of debt was $264.3 million, versus $5.1 million a year earlier.
Midpoint 2025 guidance raised to 181.5 MBbls/d for oil and 394.0 MBoe/d for total production; fourth quarter base dividend declared at $0.15 per share, payable December 31, 2025.
CONMED reported third quarter 2025 sales of $337.9 million, up 6.7% year over year, while GAAP diluted EPS fell to $0.09 from $1.57 a year earlier, after product rationalization costs and other charges. The company also raised the midpoint of its adjusted EPS guidance, authorized a $150.0 million share repurchase program, and suspended its quarterly cash dividend, which matters to shareholders because it changes how cash is returned to them.
Q3 2025 sales were $337.9 million, up 6.7% as reported and 6.3% in constant currency.
GAAP diluted EPS was $0.09 versus $1.57 in Q3 2024; adjusted diluted EPS was $1.08 versus $1.05.
Full-year 2025 adjusted diluted EPS guidance is $4.48 to $4.53, compared with the prior $4.40 to $4.55.
Board authorized a $150.0 million buyback effective October 31, 2025 and suspended the quarterly dividend; at least $25.0 million in annual repurchases is expected from 2026.
Crescent Energy filed unaudited pro forma financial statements that show how its Ridgemar and SilverBow acquisitions, and its pending all-equity Vital Transaction, would have affected its results if they had closed on January 1, 2024. The filing is illustrative and not an actual reported quarter, but it indicates that the combined company would have reported higher net income for the nine months ended September 30, 2025 than Crescent reported on a historical basis.
Ridgemar acquisition closed January 31, 2025, for $830.0 million in cash plus 5,454,546 Class A shares, with up to $170.0 million in earn-out payments tied to WTI prices in 2026 and 2027.
Vital Transaction is an all-equity deal under a Merger Agreement disclosed August 25, 2025; the pro forma statements include it.
Pro forma net income attributable to Crescent for the nine months ended September 30, 2025 was $154.7 million, compared with $141.6 million historical.
For the year ended December 31, 2024, pro forma net income attributable to Crescent was $84.9 million, compared with a historical net loss of $114.6 million.
CoreCivic reported third-quarter 2025 revenue of $580.4 million, up 18.1% from a year earlier, and net income of $26.3 million, or $0.24 per diluted share. It lowered its full-year 2025 guidance, citing start-up expenses at four newly contracted facilities that it expects to weigh on fourth-quarter results, while saying those facilities should support stronger 2026 results.
Q3 2025 net income was $26.3 million, or $0.24 per diluted share, compared with $21.1 million, or $0.19, in Q3 2024.
Full-year 2025 net income guidance was revised to $107.0 million to $113.0 million, down from $116.4 million to $124.4 million.
Full-year 2025 adjusted EBITDA guidance was revised to $355.0 million to $359.0 million, down from $365.0 million to $371.0 million.
In Q3 2025 the company repurchased 1.9 million shares for $40.0 million; $197.9 million of repurchase authorization remained as of September 30, 2025.
Acadia Pharmaceuticals reported third quarter 2025 total revenue of $278.6 million, up 11% from a year earlier, and net income of $71.8 million, or $0.42 per diluted share, compared with $32.8 million a year earlier. The company raised its 2025 NUPLAZID net product sales guidance and lowered the top of its DAYBUE sales range while narrowing it; the net income gain includes a one-time tax benefit.
Q3 2025 total revenue of $278.6 million, up 11% year-over-year; NUPLAZID sales $177.5 million and DAYBUE sales $101.1 million
Q3 net income of $71.8 million ($0.42 diluted) vs. $32.8 million ($0.20) in Q3 2024, including a one-time tax benefit tied to the One Big Beautiful Bill Act
2025 total revenue guidance of $1.070 to $1.095 billion, vs. prior $1.045 to $1.095 billion; NUPLAZID guidance raised to $685 to $695 million from $665 to $690 million
Cash, cash equivalents and investment securities of $847.0 million at September 30, 2025
Pursuit Attractions and Hospitality reported third quarter 2025 revenue of $241.0 million, up 32.2% from a year earlier, and net income attributable to Pursuit of $73.9 million, versus $48.6 million. The company raised its full-year 2025 adjusted EBITDA guidance to $116 million to $122 million, an increase of $6 million at the midpoint, which points to higher expected profit for shareholders.
Q3 2025 revenue was $241.0 million, up $58.8 million from $182.3 million in Q3 2024.
Diluted EPS attributable to Pursuit was $2.60, versus $1.65; adjusted EBITDA was $117.4 million, versus $82.9 million.
Full-year 2025 adjusted EBITDA guidance was raised to $116 million to $122 million from $108 million to $118 million.
Q3 results included a $4.2 million pre-tax gain from business interruption insurance proceeds tied to the 2024 Jasper wildfire.
Encore Capital Group reported third quarter 2025 results on November 5, 2025, with diluted earnings per share of $3.17, up from $1.26 a year earlier, and total revenues of $460.4 million, up 25%. The company raised its full-year 2025 collections guidance to approximately $2.55 billion, which it says reflects 18% growth, and its board added $300 million to its share repurchase program.
Diluted EPS was $3.17 versus $1.26 a year earlier; net income was $74.7 million, up 144%.
Collections were a record $663 million, up 20%, including $502 million in the U.S.
Full-year 2025 collections guidance was raised to approximately $2.55 billion; portfolio purchasing guidance was unchanged.
About $60 million of shares were repurchased year-to-date, and the board added $300 million to the repurchase program.
Coherent Corp. reported first quarter fiscal 2026 revenue of $1.58 billion, up 17% from a year earlier, with GAAP diluted EPS of $1.19 versus a loss of $0.04 a year earlier. The company also gave second quarter revenue guidance of $1.56 billion to $1.70 billion and non-GAAP EPS guidance of $1.10 to $1.30, and it closed the sale of its Aerospace and Defense business.
Q1 revenue $1.58 billion, up 17.3% year over year; 19% on a pro forma basis, adjusted for the Aerospace and Defense sale
Q1 GAAP diluted EPS $1.19 versus $(0.04) a year earlier; non-GAAP diluted EPS $1.16, up from $0.67
Q2 fiscal 2026 guidance: revenue $1.56 billion to $1.70 billion; non-GAAP EPS $1.10 to $1.30
Paid down $400 million of debt in the quarter and refinanced its debt; Q1 GAAP net earnings include a $115.2 million gain on the business sale
ADMA Biologics reported third quarter 2025 total revenue of $134.2 million, up 12% from a year earlier, and GAAP net income of $36.4 million, up from $35.9 million. The company raised its full-year 2025 revenue guidance to at least $510 million and its 2026 revenue guidance to at least $630 million, but lowered 2025 adjusted net income guidance to approximately $158 million from more than $175 million because of a higher effective tax rate.
Q3 2025 GAAP net income was $36.4 million versus $35.9 million in Q3 2024; adjusted EBITDA was $58.7 million, up 29%.
Gross margin was 56.3% versus 49.8% a year earlier.
FY 2025 revenue guidance raised to at least $510 million; FY 2025 adjusted net income revised to approximately $158 million from more than $175 million.
FY 2026 revenue guidance raised to at least $630 million; FY 2026 adjusted EBITDA guidance raised to more than $355 million.
TKO Group Holdings reported third-quarter 2025 revenue of $1.120 billion, down 27% from the prior year, mainly because the prior-year period included IMG revenue from the 2024 Paris Olympics. Net income rose to $106.8 million from $3.4 million, and Adjusted EBITDA increased 59% to $360.2 million, so profit and guidance improved while revenue declined. The company raised its full-year 2025 revenue and Adjusted EBITDA targets.
Q3 2025 revenue was $1.120 billion, down $420.8 million (27%) from the prior-year period, primarily due to IMG's prior-year Paris Olympics revenue.
Net income was $106.8 million versus $3.4 million a year earlier; Adjusted EBITDA was $360.2 million, up 59%.
Full-year 2025 revenue guidance was raised to $4.690 billion to $4.720 billion, and Adjusted EBITDA guidance to $1.570 billion to $1.580 billion.
Free cash flow was $398.9 million versus $151.0 million a year earlier; cash and equivalents were $861.4 million and gross debt was $3.759 billion as of September 30, 2025.
Acadia Healthcare reported third-quarter 2025 revenue of $851.6 million, up 4.4% year over year, but diluted earnings per share fell to $0.40 from $0.74 and adjusted EBITDA fell to $173.0 million from $194.3 million. The company lowered its full-year 2025 revenue, adjusted EBITDA and adjusted EPS guidance, and COO Dr. Nasser Khan resigned effective November 3, 2025.
Q3 revenue $851.6 million, up 4.4%; same-facility admissions up 3.3%
Net income attributable to Acadia $36.2 million, or $0.40 per diluted share, vs $0.74 a year earlier
Full-year adjusted EBITDA guidance cut to $650 million to $660 million from $675 million to $700 million
Dr. Nasser Khan resigned as COO effective November 3, 2025; receives a $515,000 lump-sum payment by March 15, 2026
Remitly reported third-quarter 2025 revenue of $419.5 million, up 25% from a year earlier, and net income of $8.8 million, compared with $1.9 million. The company raised its full-year 2025 revenue and Adjusted EBITDA outlook, which gives shareholders a higher expected range for the year.
Q3 2025 revenue was $419.5 million, up from $336.5 million; send volume rose 35% to $19.5 billion.
Q3 net income was $8.8 million versus $1.9 million a year earlier; Adjusted EBITDA was $61.2 million, up 29%.
Full-year 2025 revenue outlook is $1.619 billion to $1.621 billion, up from $1.610 billion to $1.620 billion; Adjusted EBITDA outlook is $234 million to $236 million, up from $225 million to $230 million.
Q4 2025 revenue is expected at $426 million to $428 million, growth of 21% to 22%.
Schrödinger reported third-quarter 2025 total revenue of $54.3 million, up 54% from a year earlier, and a net loss of $32.8 million, narrower than the $38.1 million loss in the prior-year quarter. The company lowered its full-year 2025 software revenue growth guidance to 8% to 13% from 10% to 15%, and said it expects savings of approximately $70 million from expense-reduction measures and a shift away from independent clinical development.
Q3 total revenue was $54.3 million, up 54%; software revenue was $40.9 million, up 28%, and drug discovery revenue was $13.5 million versus $3.4 million a year earlier.
Full-year 2025 software revenue growth guidance was cut to 8% to 13% from 10% to 15%, while drug discovery revenue guidance was raised to $49 million to $52 million from $45 million to $50 million.
Q3 net loss was $32.8 million, versus $38.1 million in Q3 2024; non-GAAP net loss was $42.3 million.
Cash, cash equivalents, restricted cash and marketable securities totaled $401.0 million at September 30, 2025.
CRH reported third-quarter 2025 revenue of $11.1 billion, up 5% from a year earlier, with net income of $1.5 billion (up 9%) and diluted EPS of $2.21 (up 12%). The company reaffirmed its 2025 net income guidance of $3.8 billion to $3.9 billion and raised the midpoint of its adjusted EBITDA guidance to $7.65 billion from $7.6 billion, while also declaring a quarterly dividend of $0.37 per share, up 6%.
Q3 2025 revenue $11.1 billion (up 5%); net income $1.5 billion (up 9%); diluted EPS $2.21 (up 12%)
Adjusted EBITDA $2.7 billion (up 10%); net income margin 13.7%, adjusted EBITDA margin 24.3%
2025 guidance: net income reaffirmed at $3.8 billion to $3.9 billion; adjusted EBITDA midpoint raised to $7.65 billion from $7.6 billion
Quarterly dividend of $0.37 per share, payable Dec. 17, 2025, to holders of record Nov. 21, 2025; net debt rose to $15.0 billion from $10.5 billion at December 31, 2024
Dutch Bros reported third-quarter 2025 results on November 5, 2025, with total revenue up 25.2% to $423.6 million and net income of $27.3 million, compared with $21.7 million a year earlier. The company raised its full-year 2025 total revenue guidance to between $1.61 billion and $1.615 billion, while its Adjusted EBITDA guidance of $285 million to $290 million was unchanged.
Q3 2025 total revenue rose 25.2% to $423.6 million from $338.2 million; diluted EPS was $0.14 versus $0.11
Systemwide same shop sales rose 5.7%, with transactions up 4.7%; the company says the trend continued through October
2025 total revenue guidance raised to $1.61 billion to $1.615 billion; same shop sales growth now expected at about 5%
Company-operated shops gross margin was 21.0%, down 120 basis points year over year
Kemper reported a third-quarter 2025 net loss of $21.0 million, or $(0.34) per share, compared with net income of $73.7 million, or $1.14 per diluted share, a year earlier. Revenue rose to $1,239.7 million, but Specialty Property & Casualty results weakened, and the company called the quarter disappointing and below its expectations.
Q3 2025 net loss of $21.0 million, or $(0.34) per share, versus net income of $73.7 million, or $1.14 per diluted share, in Q3 2024
Adjusted Consolidated Net Operating Income was $20.4 million, or $0.33 per diluted share, versus $105.0 million, or $1.62 per diluted share, a year earlier
Specialty P&C Underlying Combined Ratio rose to 99.6 percent from 91.3 percent; total revenues increased $60.8 million to $1,239.7 million
Repurchased about 5.1 million shares for about $266 million from July 1 through October 31, 2025
QuidelOrtho reported third-quarter 2025 results with revenue of $700 million, down 4% from $727 million a year earlier, mainly due to lower COVID-19 and Donor Screening revenue. A $701 million non-cash goodwill impairment charge drove a GAAP net loss of $733 million, while adjusted diluted EPS was $0.80 versus $0.85 and adjusted EBITDA rose to $177 million from $171 million. The company narrowed its full-year 2025 revenue and adjusted EBITDA guidance ranges and updated adjusted EPS guidance to $2.00 to $2.15 to reflect its debt refinancing.
Q3 2025 total revenue was $700 million, down 4% as reported; non-respiratory revenue rose 5% as reported
GAAP diluted loss per share was $10.78 versus a $0.30 loss a year earlier, including a $701 million goodwill impairment charge
Adjusted EBITDA was $177 million, a 25% margin, compared with $171 million and 23% a year earlier
Full-year 2025 guidance: revenue $2.68 to $2.74 billion, adjusted EBITDA $585 to $605 million, adjusted diluted EPS $2.00 to $2.15
Jazz Pharmaceuticals reported third-quarter 2025 total revenue of $1.13 billion, up 7% from a year earlier, and GAAP net income of $251.4 million, or $4.08 per diluted share, compared with $215.1 million, or $3.42 per share, in the prior-year quarter. The company raised its 2025 non-GAAP adjusted net income guidance to $475 million to $525 million from $300 million to $350 million, but nine-month GAAP results show a net loss of $559.6 million due to a large acquired in-process R&D charge and litigation settlements.
Q3 2025 total revenues were $1,126.1 million, up from $1,055.0 million in Q3 2024.
GAAP net income was $251.4 million ($4.08 per diluted share) versus $215.1 million ($3.42) a year earlier.
2025 non-GAAP adjusted net income guidance rose to $475 million-$525 million from $300 million-$350 million.
Nine-month GAAP net loss was $559.6 million, compared with net income of $369.0 million in the prior-year period.
Southwest Gas Holdings said its Senior Vice President and Chief Financial Officer, Robert J. Stefani, will leave the role effective December 1, 2025, or earlier if his employment ends sooner. The filing says the departure is not tied to any disagreement with auditors or management on accounting, disclosure, or internal controls, and the board has started a search for a successor.
Robert J. Stefani, SVP and CFO of Southwest Gas Holdings and Southwest Gas Corporation, will leave the role effective December 1, 2025 or earlier separation date
Grand Canyon Education reported third quarter 2025 service revenue of $261.1 million, up 9.6% from a year earlier, but diluted earnings per share fell to $0.58 from $1.42 after a $35.0 million reserve for the settlement of a qui tam lawsuit. The company also gave fourth quarter and full year 2025 outlook, including full year diluted EPS of $7.66 to $7.77 on a GAAP basis, which includes the litigation reserve.
Q3 service revenue rose 9.6% to $261.1 million; GCU online enrollments rose 9.6% to 107,815.
Q3 net income fell 60.8% to $16.3 million; diluted EPS was $0.58 versus $1.42. Adjusted diluted EPS was $1.78 versus $1.48.
Full year 2025 guidance: service revenue of $1,103.0 million to $1,108.0 million and diluted EPS of $7.66 to $7.77 (adjusted $9.02 to $9.13).
Unrestricted cash and investments were $277.0 million at September 30, 2025, down from $324.6 million at December 31, 2024.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.